Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H4


Brief Information

Name:V-set domain-containing T-cell activation inhibitor 1
Target Synonym:V-Set Domain-Containing T-Cell Activation Inhibitor 1,Immune costimulatory protein B7-H4,B7h.5,B7 homolog 4,T-cell costimulatory molecule B7x,V-Set Domain Containing T Cell Activation Inhibitor 1,B7X,B7 Family Member, H4,T Cell Costimulatory Molecule B7x,B7S1,B7 Superfamily Member 1,VCTN1,PRO1291,FLJ22418,B7H4,B7-H4,Protein B7S1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data


Anti-B7-H4 antibody, Human IgG1 captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Canine B7-H4, His Tag (Cat. No. B74-C52H8) with an affinity constant of 8.59 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Rat B7-H4, His TagRat B7-H4, His Tag (Cat. No. B74-R52H9) ELISA bioactivity

Immobilized Rat B7-H4, His Tag (Cat. No. B74-R52H9) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H4 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (QC tested).

Customer Reviews

Synonym Name



V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
AZD-8205 AZD-8205 Phase 2 Clinical Astrazeneca Plc Ovarian Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Endometrial Neoplasms Details
NC-762 NC-762 Details
HS-20089 HS-20089 Phase 1 Clinical Shanghai Hansoh Biomedical Co Ltd Solid tumours Details
PF-07260437(Pfizer) PF-07260437 Pfizer Inc Details
SGN-B7H4V SGN-B-7H-4V; SGNB-7H4V; SGNB-7H-4V; SGN-B7H4V Seagen Inc Details
XMT-1660 XMT-1660 Phase 1 Clinical Mersana Therapeutics Inc Ovarian Neoplasms; Abdominal Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Breast Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms Details
Alsevalimab FPA-150 Phase 1 Clinical Five Prime Therapeutics Inc Solid tumours; Ovarian Neoplasms; Neoplasms; Breast Neoplasms; Endometrial Neoplasms Details
HBM-7008 HBM7008; HBM-7008; R-7008 Phase 1 Clinical Harbour Biomed Solid tumours Details
GEN-1047 GEN-1047 Phase 2 Clinical Genmab A/S Ovarian Neoplasms; Breast Neoplasms; Uterine Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message